The short version of REV-ERB fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-29. Anything still debated is marked as such rather than presented as settled.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
=== Long-term === Finasteride may cause persistent adverse sexual, neurological, and physical effects in a subset of men. A 2019 systematic review surveyed the literature on the reversibility of finasteride's side effects. It identified three studies that demonstrated full reversibility of side effects and eleven that described patients with irreversible adverse events. A separate 2017 retrospective review of nearly 12,000 patients found 1.4% developed persistent (lasting at least 90 days after stopping Finasteride) ED, with this dropping to 0.8% for 16-42 year olds.
Starfish embryos typically hatch as blastulas. Invaginations take place; the first, forming the anus, is created from the blastopore, while a second, taking place in the ectodermic layer, creates the mouth. The archenteron stretches towards the mouth and connects with it, forming the gut. A band of cilia develops on the exterior. This enlarges and extends around the surface and eventually onto two developing arm-like outgrowths. At this stage the larva is known as a bipinnaria. The cilia are used for locomotion and feeding, their rhythmic beat wafting phytoplankton towards the mouth. The next stage in development is a brachiolaria larva, and involves the growth of three short ventral-anterior arms with adhesive tips surrounding a sucker. Both bipinnaria and brachiolaria larvae are bilaterally symmetrical. When fully developed, the brachiolaria settles on the seabed and attaches itself with a short stalk made from its ventral arms and sucker. Metamorphosis now takes place with a radical rearrangement of tissues. The larvae develops an oral surface on the left and an aboral surface on the right. While the gut remains, the mouth and anus move to new positions. Some of the body cavities disappear while others become the water vascular system and the visceral coelom. The starfish is now pentaradially symmetrical. It casts off its stalk and becomes a free-living juvenile starfish up to 1 mm (0.04 in) in diameter.
A vinyl sulfone is an organic compound with the formula O2S(CH=CH2)2. The molecule consisting of two vinyl groups bonded to a sulfone. It is the parent of several vinyl sulfones of the type O2S(CH=CH2)R. Many vinyl sulfones are known.
=== Inherent instability of the enediyne core === The instability toward Bergman cyclization–reduction decomposition pathways poses a major threat to any proposed synthesis of enediynes. Myers and co-workers addressed this liability by late-stage dehydrative installation of the olefin. Without this unsaturation linking the two alkynyl bridges, synthetic intermediates are not disposed toward Bergman-type decomposition, and risk of decomposition is mitigated. In this case, dehydration of a propargylic alcohol was induced by treatment with Martin sulfurane.
Sources: en.wikipedia.org
=== Novel Vaccine Adjuvant === A novel vaccine adjuvant that's purpose is to evoke both humoral and cellular immune responses was reported. This vaccine adjuvant was found from a supramolecular hydrogel of a self-assembling D-tetra-peptide. Prior pioneering work has found that self-assembling peptides can serve as self-adjuvated vaccines through the covalent conjugation of peptide or protein antigens, but that cannot elicit strong CD8^+ T-cell responses. However, in a recent study it has been found that the self-assembling L-peptide derivative (Nap-GFFY-NMe, naphthylacetic acid modified tetra-peptide of GFFY with C-terminal methyl amide group) that was formed fromm the phosphatase, could co-assemble with HIV DNA molecules and raise both humoral and cellular immune responses against HIV. It has been reported that the large-scale synthesis of the phosphorylated precursor (Nap-GFFpY-NMe or Nap-GFFpY-OMe (naphthylacetic acid modified phosphorylated tetra-peptide of GFFpY with C-terminal methyl ester group)) is extremely difficult. It has also been reported that the need of enzyme triggering could possibly cause side effects including; reproducibility problems and composition variation. If they are able to develop a peptide hydrogel as a vaccine adjuvant that contains a well-defined molecular structure and a very simple formulation mode, it would be very promising.
== Side effects == Side effects of etifoxine include slight drowsiness and headache. Rarely, etifoxine can cause benign skin eruptions or rashes and allergic reactions such as hives and angioedema. Etifoxine shows less adverse effects of anterograde amnesia, sedation, impaired psychomotor performance, and withdrawal syndromes than those of benzodiazepines. No cases of misuse or dependence with etifoxine were identified in a French pharmacovigilance survey, which is also in contrast to benzodiazepines. Etifoxine has been associated rarely with cases of severe dermal toxicity and liver toxicity. Skin and subcutaneous disorders are the most frequently reported, but these generally resolve after drug cessation. A 2012 review of etifoxine by the French National Pharmacovigilance Committee determined that etifoxine was safe and continued to provide a favorable alternative to benzodiazepine anxiolytics. The committee found (for a ten-year pharmacovigilance period) that safety concerns were rare or very rare and that the incidence of idiosyncratic hepatic (liver) problems were very rare.
=== Motivational disorders === Selegiline has been found to produce pro-motivational effects and to reverse motivational deficits in rodents. In case reports and small clinical studies, selegiline has been reported to improve disorders of diminished motivation like apathy and abulia due to conditions such as traumatic brain injury. In accordance with the preceding findings, selegiline, along with other dopaminergic and activating agents, may be useful in the treatment of disorders of diminished motivation, including apathy, abulia, and akinetic mutism.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.